Develops monoclonal antibodies for spinal muscular atrophy and muscular dystrophy.
Dec 2025Revenue $0.00/yrExpenses $385M/yr
No trendCash runway ≈ 1.7 years from Jun 2026
Figures by year
When will Scholar Rock Holding be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $0.00 and expenses $385M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $385M | −$385M |
| Dec 2022 | $33.2M | $168M | −$134M |
| Dec 2021 | $18.8M | $149M | −$130M |
| Dec 2020 | $15.4M | $102M | −$86.9M |
| Dec 2019 | $20.5M | $75.0M | −$54.5M |
| Dec 2018 | $0.00 | $50.7M | −$50.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.